aging gracefully with hiv jonathan s. appelbaum, md, facp, aahivs
TRANSCRIPT
Aging Gracefully with HIV
Jonathan S. Appelbaum, MD, FACP, AAHIVS
Disclosure of Financial RelationshipsThis speaker has the following financial relationships with commercial entities to
disclose:• Salary/Contractual Services: Merck – Terminated
This speaker will not discuss any off-label use or investigational product during the program.
This slide set has been peer-reviewed to ensure that there are no conflicts of interest represented in the presentation.
Objectives
• Implement the newest screening and treatment guidelines for osteoporosis, hyperlipidemia and cancer screening as it pertains to HIV patients
• Identify additional screening needs and proper treatment of HIV patients that are not recommended for the general population
Case 1
• 95 yo AAF previously well presents with FTT and memory problems for the past several years
• PMH: HTN, depression, h/o corneal transplant
• Meds: HCTZ, fluoxetine• Soc: lives with daughter, husband died
1995. No Tobacco, ETOH, IDU
On Exam• Thin woman (BMI 19)• Good skin turgor, no rashes• Edentulous, white plaque on posterior
pharynx• No lymphadenopathy or palpable thyroid• Lungs and cardiac exam WNL• No abdominal masses, stool heme neg• MMSE 24• Neuro exam non-focal
How would you prioritize this work up?
A. CBC/LFT’s/thyroid function tests
B. EGD/Colonoscopy
C. Chest/Abdomen/ Pelvic CT
D. HIV test
E. A first, then D, then B&C if needed
A. B. C. D. E.
0% 0% 0%0%0%
The tests return…..• CMP, TSH normal• Mild normocytic normochromic anemia• EGD, colonoscopy negative• chest/abdomen/pelvic CT normal • HIV Ab+, CD4=141 VL=250K• Other Labs: RPR+ 1:8
CDC Recommendations for HIV Testing
(from MMWR, September 26, 2006, 55(RR 14); 1-17)
Epidemiology
• Increasing Prevalence– Prolonged survival due to HAART– New Infections
Why are older patients getting infected?
Why do you think that the number of older patients with HIV is
increasing?
Why are older patients getting infected?
• Patient lack of awareness of HIV risk factors (sex and drugs)– Many older people are newly single – Belief that HIV only affects younger people
• Unprotected sexual activity– Use of sildenafil and other ED drugs may contribute to
increased rates of sexual activity – Menopause= No risk for pregnancy=No condom– No training in safer sexual activities
• Lack of HIV prevention education targeted at older people
• Seniors not considered at risk: don’t ask, don’t tell
Sex is Not Only for the Young
Lindau NEJM 2007 357(8):762-774
Pro
port
ion
repo
rtin
g se
x in
last
12
mon
ths
57-64 65-74 75-850.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
83.7
67.0
38.5
61.6
39.5
16.7
Men Women
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 20070
50
100
150
200
250
300
350
400
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
269 277 275284
293313
296312
323333 336
203 211
246261
234
272 274261
272 273 266
<50 years ≥50 years <50 years
Me
dia
n C
D4
co
un
t (c
ells
/mm
3)
at
firs
t p
res
en
tati
on
fo
r H
IV c
linic
al c
are
Pro
po
rtio
n o
f p
ati
en
ts w
ith
a C
D4
co
un
t ≥
35
0
ce
lls/m
m3
at
firs
t p
res
en
tati
on
fo
r H
IV c
linic
al c
are
Median CD4 count and the percentage of patients with a CD4 count ≥350 cells/mm3, at first presentation for HIV
clinical care, by age
<50yo: absolute increase in median CD4 = 67 cells/mm3
≥50yo: absolute increase in median CD4 = 63 cells/mm3
Althoff, AIDS Res Therapy 2010
Prevalence of AIDS, 12 Months after HIV Diagnosis by Age, 2007
HIV surveillance Report, Volume 20, CDC (2010)
Clinical Outcomes in Older Patients Treated with ART
• Virologic Suppression• Immunologic Response• Mortality
Mean Increase in CD4 by Age 2 years after ART
6 months 12 months 18 months 24 months0
50
100
150
200
250 18-<30 years 30-<40 years 40-<50 years 50-<60 years≥60 years
Months since ART initiationAlthoff K AIDS 2010
What are older HIV-infected patients dying from?
A. PCP pneumonia
B. Wasting syndrome
C. Malignancy
D. Dementia
A. B. C. D.
0% 0%0%0%
The Changing Epidemic
ART-CC. CID, 2010.
Among those initiating HAART(1996-2006)
HIV Outcomes with ART: What we Know Already
HIV-1 RNA suppression
Older >Younger, doesn’t vary by class
CD4 response Younger>Older
Mortality Older >Younger, usually due to non HIV causes
Case #1-Follow-up
• AZT/3TC/ABC/EFV: – Developed hallucinations
• AZT/3TC/ABC/LPV/r: – Hepatitis
• TDF/FTC/atazanavir: – Renal insufficiency
• ABC/3TC/atazanavir: – Undetectable, CD4 400
Recommendations When to Initiate Therapy
• Antiretroviral therapy should be initiated in all patients older than 50 who have a CD4 count < 500 cells/mm3 .
• Antiretroviral therapy should be initiated in all patients older than 50, regardless of CD4 cell count, with the following conditions: AIDS-defining illness, HIV-associated nephropathy, or chronic hepatitis B virus infection.
• For patients over age 50 who have a CD4 count > 500 cells/mm3, antiretroviral therapy should be considered. Factors favoring initiating therapy include plasma HIV RNA levels greater than 50,000 copies/ml, greater than 100-point decline in CD4 count in prior 12 months, or risk factors for cardiovascular disease.
Normal Aging Process
• Loss of Bone and Muscle Mass
• Weight Loss• Decrease in GFR• Memory Loss• Immunosenescence
Treatment Issues in Older HIV Patients
• Older people may have age-related losses of kidney and/or liver function which may change metabolism of drugs
• Drug-drug interactions• Toxicities significant• Older people often excluded from
many clinical trials and few subgroup analysis in older patients
• Little pharmacokinetic data at extremes of age
Case #2• 63 yo AAF HIV x 10 yrs, CD4 420, VL <50• PMH: HTN, depression, DM, hyperlipidemia• Meds: emtricitabine/tenofovir/efavirenz,
HCTZ, citalopram, glargine insulin, lisinopril, EcASA, pravastatin
• SH: lives alone, No tobacco,, IDU, has boyfriend and uses condoms intermittently
• Difficulty with adherence to non-ART medicines
• HbA1C >10, SBP >160
Number of non-HIV meds by age
B Haase CROI 2011
0
20
40
60
80
100
% o
f par
ticip
ants
<50 years 50-64 years 65+ years
Age
4+
3
2
1
0
Number ofco-medications
Incidence of comorbidities: by age
B Haase CROI 2011
Ba
cte
ria
l pn
eu
mo
nia
Ce
reb
ral i
nfa
rctio
n
Co
ron
ary
an
gio
pla
sty
Myo
card
ial i
nfa
rctio
n
Pro
ced
ure
s o
n o
the
r a
rte
rie
s
Pu
lmo
na
ry e
mb
olis
m
Fra
ctu
re,
ad
eq
ua
te t
rau
ma
Fra
ctu
re,
ina
de
qu
ate
tra
um
a
Ost
eo
po
rosi
s
Dia
be
tes
me
llitu
s
No
n A
IDS
de
finin
g m
alig
na
nci
es
AID
S d
efin
ing
eve
nt
De
ath
12
51020
0.10.2
0.5Age 50-64 yearsAge <50 years
Age 65+ years
50In
cid
en
cep
er
10
00
pyr
s (9
5%
CI)
Potential Comorbidities Among Older Patients With HIV
• Cardiovascular disease• Metabolic disorders
– Diabetes– Dyslipidemias
• Neurocognitive abnormalities• Liver and renal problems• Bone disorders
– Osteopenia– Osteoporosis
• Malignancies
Age at cancer diagnosis among people with AIDS and in the general population 1980-2006
Observed Expected in age adjusted group
P value
NHL 39 43 <.001
Cervical 39 41 .03
Rectal 46 51 .002
Lung 49 53 .001
Hodgkin's 41 38 <.001
Breast 44.5 45 .2
Prostate 59 59 .5
Shiels Annals of Int Med 2011
• For most cancers: there is no difference in age at cancer diagnosis among persons with AIDS compared to the general population.
Case #3• 64 yo WM, HIV+ 22 years, no OIs.• Smokes 1 ppd x 40 yrs• Multiple ART, now on boosted darunavir,
etravirine, raltegravir• CD4 321, HIV RNA <48 c/ml3
• Facial lipoatrophy, truncal lipohypertrophy
• Other meds: metformin, lisinopril, ASA• Reports decreased libido and ED
To evaluate this patient’s concerns, he should have:
A. CBC/LFT’s/thyroid function tests
B. PSA
C. Free Testosterone
D. Total Testosterone
E. All of the above
A. B. C. D. E.
0% 0% 0%0%0%
Endocrine• Testosterone Def: 54% had testosterone
<300 ng/dL. • Low androgen levels were associated with
increasing age, HIV+ IDU, HCV+ and use of psychotropic medications
• Menopause: Occurs at younger age in HIV infection 46 (IQR 39-49)
• Associated with increased symptoms of estrogen withdrawal
Klein CID 2005; Schoenbaum E CID 2005
Which of the following recommendations should be your first counseling priority?
A. Diet?
B. Smoking?
C. Exercise?
D. BP control?
E. DM management?
A. B. C. D. E.
0% 0% 0%0%0%
Law et al. HIV Med. 2006;7:218-230.
0
1
2
3
4
5
6
7
8
Duration of cART exposure (years)
Rat
es p
er T
ho
usa
nd
Pat
ien
t-Y
ears
<1 1-2 2-3 3-4 4+
Observedrates
Best estimate of predicted
rates
None
Observed and predicted MI rates according to ART exposure(D:A:D Study n=23,468)
N=5292 N=6805 N=9050 N=10,574 N=8890N=5973
Incidence of MIs is low: 345 over 94,469 patient-years follow-up (3.7/1,000 patient-years)
D:A:D Study: Is the Framingham Risk Estimation Valid in HIV-Infected Patients?
n = ART exposure
D:A:D Study: Risk Factors for CHD in an HIV+ Population
Lundgren J, et al. 12th CROI; 2005; Boston. Abstract 62. Copenhagen HIV Programme (D.A.D)
Relative Rate of Myocardial Infarction (95% CI)Adjusted for BMI, HIV risk, cohort, calendar year and race
Diabetes mellitus (yes versus no)
Hypertension (yes versus no)
Better Worse
0.1 0.5 1 5 10
Family history
Previous CVD
Male gender
Age per 5 years older
Smoking
Drug class: not sufficient # of events to examine yet
cART Therapy RR 1.17 (1.08-1.26)
Case #3—follow-up• Free/total testosterone decreased• PSA, CBC, LFTs normal• Started on testosterone replacement• Appropriate lab follow up done, no
improvement in symptoms• Sildenafil added (dose-adjusted) with
improvement
Recommendations: Lipids• There is insufficient evidence to alter
current recommendations for management of dyslipidemia or CVD/ cerebrovascular disease screening by specific age criteria.
• Use Framingham Risk Score to guide decision.
Case #4
• 77 yo WM HIV x 20 years, CD4 750, VL<50
• PMH: depression, HCV+• Meds: tenofovir/emtricitabine, atazanavir
with ritonavir• SH: lives alone, divorced, MSM, 2
children, 4 grandchildren; no tobacco/ IDU, rare ETOH
Should this patient be screened for osteoporosis?
A. Yes
B. No
C. Don’t Know
A. B. C.
0% 0%0%
BMD Decreases With Age
Orwoll ES et al. Endocr Rev. 1995;16(1):87-116.
Ch
ang
e in
Bo
ne
Vo
lum
e (%
)
Age (Years)40 50 60 70
10
15
20
25
30
Mean ±SE
MaleFemale
Case #4 (con’t)
• 77 yo WM HIV x 20 years, CD4 750, VL<50
• Meds: tenofovir/emtricitabine, atazanavir plus ritonavir
• SH: lives alone, divorced, MSM, 2 children, 4 grandchildren; no tobacco/ IDU, rare ETOH
• January 2011 Ice storm• Falls and breaks multiple bones
BMD Lower and Fracture prevalence higher in HIV infection
• BMD lower in HIV+ men at the femoral neck (p<.05) and lumbar spine ( p=0.06);
• Differences significant after adjusting for age, weight, race, testosterone level, and prednisone and IDU
• A 38% increase in fracture rate among HIV+ men
Triant J Clin Endo Metab 2008
Arnsten AIDS 2007
Recommendations: Osteoporosis Screening
• Since older patients have bone loss due to osteoporosis, and since many HIV-infected patients on ART have accelerated bone loss, screening for (and aggressive treatment of) osteoporosis should be done
• Since vitamin D deficiency is prevalent in older HIV-infected persons, screening for vitamin D deficiency is warranted
Frailty• Frailty phenotype: 3 of 5 (weight loss,
exhaustion, weakness, slowness, and low physical activity). – earlier occurrence in HIV-infected patients
• Functional status – may be better indicator
Frailty increases with age and time with HIV
Desquilbet, et al. J Gerontol Med Sci 2007;62A:1279-86
HIV-infected for 8-12 years at age 55 13.4% exhibit the frailty phenotype –
9-fold higher risk than age-matched controls
VACS Risk Index
Points HR
Age <5050-64>65
0927
1.01.452.94
CD4 <5050-99100-199200-349>350
17141180
1.981.721.541.381.00
AIDS def. illness 7 1.31
HIV-1 RNA >5.0 Log 3 1.14
Hemoglobin >1210-12<10
0913
1.001.431.67
FIB-4 <1.451.45-3.24>3.25
01018
1.001.502.09
est GFR<30 12 1.61
ETOH or Drug Use 8 1.35
Hep B or HCV 9 1.45
Justice 2010 HIV Medicine
VACS - Veterans Aging Cohort Study
Survival by VACS Risk Score(6 Years)
Justice 2010 HIV Medicine
Case 5 Presentation
• 77 yo AAF HIV x 5 years, CD4 500, VL<50
• PMH: HTN, arrhythmia with AICD, depression,
• Meds: tenofovir/emtricitabine/efavirenz, carvedilol, HCTZ, citalopram, pravastatin
• SH: Caretaker for grandchildren, husband died 2008, No tobacco, ETOH, IDU
• Family is unaware of diagnosis, impacts adherence to ART
General Routine Health Maintenance
• All Medications• Tobacco/ETOH/drug use• Nutrition• Injury Prevention: Burns/Falls/Driving• Bowel Habits/Incontinence• Psychosocial issues-$, end-of-life,
social support and assisted living/SNF
Recommendations: Cancer Screening• As part of general health maintenance practices,
cancer screening in clinically stable HIV-infected patients 50 years and older should be in accordance to current guidelines for the general population.
• For cervical cancer, anal cancer, and liver cancer where HIV-specific recommendations exist, these guidelines should be adhered to instead.
• For all patients, providers should take into consideration functional status and life expectancy in applying these recommendations.
When to stop screening• When life expectancy less than natural
history of disease: for example, colorectal cancer
• Patient desires/expectations• Current guidelines—for example, ACP
and colon cancer screening after age 75
Other Important Issues• Sexuality• Mobility• Mentation/Depression• Hearing/Vision• Activities of daily living
Conclusions• HIV infection is increasing in the older population• Older patients present later=>need to improve
testing and linkage to care• Compared to younger patients, older HIV patients
have:– Better virologic response, less immunologic boost,
shortened survival
• Psychosocial issues and advanced directives are important
Recommendations• Start older patients with ART earlier for improved CD4 counts and
reducing comorbidities– Watch closely for side effects/toxicities
• Screen for comorbid disease (but stop screening when appropriate!)– DXA for osteoporosis
– Cancer screening
– STD’s
• Avoiding comorbid disease– Vaccinations (Flu, S. pneumoniae)
– Smoking cessation, exercise, diet
– Treat lipids, HTN
• Treat Comorbid disease– SA/MH
– HCV
• Address psychosocial issues and advanced directives
Treatment Recommendations
www.aahivm.org/hivandagingforum